Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Certain Ordinary Shares of Ascelia Pharma AB are subject to a Lock-Up Agreement Ending on 13-SEP-2021.

09/13/2021 EST

Certain Ordinary Shares of Ascelia Pharma AB (publ) are subject to a Lock-Up Agreement Ending on 13-SEP-2021. These Ordinary Shares will be under lockup for 180 days starting from 17-MAR-2021 to 13-SEP-2021. Details: The existing shareholders Sunstone Life Science Ventures Fund II K/S and Øresund-Healthcare Capital K/S, as well as the management and board of directors who hold shares in the Company at the time of the transaction, have undertaken not to sell any shares in the company for a period of 180 days, subject to customary exceptions.


ę S&P Capital IQ 2021
All news about ASCELIA PHARMA AB (PUBL)
2021Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
AQ
2021Ascelia Pharma AB Receives FDA Acceptance of IND Application for Oncoral Clinical Trial
CI
2021Results from Orviglance comparison study to gadolinium presented at RSNA 2021
AQ
2021Ascelia Pharma AB Announces Results from Orviglance comparison study to gadolinium pres..
CI
2021Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
AQ
2021QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration
AQ
2021Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed
AQ
2021Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully
CI
2021ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -126 M -14,0 M -14,0 M
Net cash 2021 252 M 27,9 M 27,9 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 919 M 102 M 102 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float -
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 27,30 SEK
Average target price 58,00 SEK
Spread / Average Target 112%
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-8.54%102
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684